Keywords: biovail, gsk, sign, million, marketing, deal, bupropion

Biovail and GSK sign $133 million marketing deal for bupropion

Article | 29 October 2001

Print This

GlaxoSmithKline and Canada's Biovail Corp have signed a deal wherebythe latter has licensed to the UK firm a novel controlled-release, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in